Irbeloc CT
Irbeloc CT - Image 2
Irbeloc CT - Image 3
,

Irbeloc CT

Contains:

  • Irbesartan IP 150 mg (Angiotensin II Receptor Blocker – ARB)

  • Chlorthalidone IP 12.5 mg (Thiazide-like Diuretic)
    Therapeutic Class: Antihypertensive (ARB + Diuretic)
    Schedule: Schedule H (Prescription Drug)

Irbeloc CT is a fixed-dose antihypertensive formulation combining Irbesartan, an angiotensin II receptor blocker, and Chlorthalidone, a long-acting thiazide-like diuretic. This combination provides synergistic blood pressure control by targeting two complementary pathways:

  • Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II.

  • Chlorthalidone promotes sodium and water excretion, reducing plasma volume and peripheral resistance.

This makes Irbeloc CT especially effective in stage 2 hypertension, salt-sensitive patients, and those with inadequate control on monotherapy.

Usage of Irbeloc CT

  • Management of essential hypertension, especially in patients not controlled with monotherapy

  • First-line therapy in patients with:

    • High cardiovascular risk

    • Obesity

    • Diabetic nephropathy or proteinuria

    • Elderly patients with isolated systolic hypertension

  • Useful in hypertensive patients with left ventricular hypertrophy

Common Side Effects

  • Irbesartan-related:

    • Dizziness or light-headedness

    • Fatigue

    • Hyperkalemia (rare)

    • GI disturbances (nausea, diarrhea)

  • Chlorthalidone-related:

    • Increased urination

    • Electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia)

    • Gout (hyperuricemia)

    • Hyperglycemia or dyslipidemia (less common at low dose)

Precautions

  • Renal impairment: Monitor renal function and serum creatinine, especially in patients with bilateral renal artery stenosis

  • Electrolyte monitoring: Check potassium, sodium, and uric acid periodically

  • Hepatic impairment: Use with caution

  • Avoid in pregnancy – Category D (ARBs can cause fetal harm)

  • Use cautiously in patients on other potassium-sparing agents, NSAIDs, or lithium

Drug Interactions

  • ACE inhibitors or other ARBs: Risk of hyperkalemia and renal impairment

  • NSAIDs: May reduce antihypertensive effect and worsen renal function

  • Potassium supplements / potassium-sparing diuretics: Risk of hyperkalemia

  • Lithium: Toxicity risk increased

  • Antidiabetic drugs: Monitor for altered glucose control with Chlorthalidone

  • Alcohol or sedatives: Additive hypotensive effect

Dosage and Administration

  • Once daily, preferably in the morning to reduce nocturnal diuresis

  • Can be taken with or without food

  • Do not crush or chew the tablet

Storage

  • Store in a cool, dry place below 25°C

  • Protect from light and moisture

Patient Counselling Tips

  • Instruct to take daily at the same time

  • Advise to rise slowly from sitting/lying positions (risk of postural hypotension)

  • Monitor for signs of dehydration, muscle cramps, or palpitations

  • Advise on regular monitoring of BP and lab tests (renal function, electrolytes)

  • Encourage salt restriction and lifestyle changes for optimal BP control

  • Avoid OTC NSAIDs or potassium supplements unless prescribed

Related products

Review My Order

0

Subtotal

Taxes & shipping calculated at checkout

Checkout